- $1.77bn
- $1.24bn
- $68.56m
U.S. STOCKS ON THE MOVE-Advanced Micro Devices, Constellation Energy, NRG Energy
U.S. STOCKS ON THE MOVE-Home Depot, Keysight Technologies, Vir Biotechnology
Vir Biotechnology soars on Q4 results beat, Astellas collaboration
Brief: Vir Biotechnology Reports Positive Updated Phase 1 Results For Psma-Targeting, Pro-Xten Dual-Masked T-Cell Engager Vir-5500
Vir Biotechnology Q4 revenue beats estimates
Brief: Vir Biotechnology Q4 EPS USD -0.31
Brief: Astellas & Vir Biotechnology Collaborate To Advance VIR-5500
Astellas collaborates with Vir to develop its experimental prostate cancer drug
U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR
Brief: Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones
Brief: Vir Biotechnology Grants Norgine Exclusive Commercial License To Chronic Hepatitis Delta Treatment Candidate
Vir Biotechnology misses Q3 revenue estimates
Brief: Vir Biotechnology Q3 EPS USD -1.17
Brief: Vir Biotechnology To Provide Corporate Update And Report Third Quarter 2025 Financial Results On November 5, 2025
Brief: Vir Biotechnology Announces First Patient Dosed In Part 3 Of Phase 1 Trial
Brief: Vir Biotechnology Q2 EPS USD -0.8
Brief: Vir Biotechnology Successfully Initiates All Trials In Eclipse Registrational Program
Vir Biotechnology Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Vir Biotechnology Q1 EPS USD -0.88